Clinical pharmacology and therapy最新文献_第6页

Efficacy and safety of olokizumab, interleukin-6 inhibitor, in hospitalized patients with COVID-19 白细胞介素-6抑制剂olokizumab治疗COVID-19住院患者的疗效和安全性

Clinical pharmacology and therapy Pub Date : 2022-06-04 DOI: 10.32756/0869-5490-2022-2-51-56

P. Novikov, M. Brovko, L. Akulkina, V. Nadtocheeva, P. Potapov, S. Moiseev

引用次数: 0

Arterial hypertension in male conscripts 男性应征入伍者的动脉高血压

Clinical pharmacology and therapy Pub Date : 2022-06-04 DOI: 10.32756/0869-5490-2022-2-37-42

B. V. Uvarovskaia, N. N. Shindryaeva, M. Astaeva, M. V. Melnik

引用次数: 0

Outcomes of breakthrough COVID-19 in hospitalized adult patients vaccinated with Gam-COVID-Vac (Sputnik V) Gam-COVID-Vac (Sputnik V)疫苗在成年住院患者中的突破效果

Clinical pharmacology and therapy Pub Date : 2022-06-04 DOI: 10.32756/0869-5490-2022-2-20-26

V. Nadtocheeva, N. Bulanov, L. Akulkina, T. Berzegova, A. Budko, M. Kalashnikov, A. Moiseev, N. Tairova, E. Tao, G. Tverdokhlebov, E. Filatova, G. Chuchin, N. Shakhgildyan, A. Schepalina, A. Suvorov, A. Kuchieva, M. Vasilyeva, P. Novikov, Y. Sorokin, V. Sholomova, M. Brovko, S. Moiseev

引用次数: 0

Constructing the function of prednisone efficacy for the treatment of inflammatory bowel diseases based on a clinical model 基于临床模型构建强的松治疗炎症性肠病疗效函数

Clinical pharmacology and therapy Pub Date : 2022-06-04 DOI: 10.32756/0869-5490-2022-2-32-36

A. Alekseeva, O. P. Alekseeva, S. V. Krishtopenko

引用次数: 0

Diagnosis and treatment of statin-induced necrotizing autoimmune myopathy 他汀类药物诱导的坏死性自身免疫性肌病的诊断和治疗

Clinical pharmacology and therapy Pub Date : 2022-06-04 DOI: 10.32756/0869-5490-2022-2-76-80

A. B. Sumarokov, M. Ezhov

引用次数: 0

Tolperisone for the treatment of low back pain 托哌利松用于治疗腰痛

Clinical pharmacology and therapy Pub Date : 2022-06-04 DOI: 10.32756/0869-5490-2022-2-14-19

N. Titova

引用次数: 0

Atypical hemolytic-uremic syndrome: clinical presentation, diagnosis and treatment 非典型溶血性尿毒症综合征的临床表现、诊断与治疗

Clinical pharmacology and therapy Pub Date : 2022-06-04 DOI: 10.32756/0869-5490-2022-2-43-50.

Y. Korotchaeva, N. Kozlovskaya, K. Demyanova, M. Alexeeva, A. Skvortsov, S. Moiseev

引用次数: 0

Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus 胰高血糖素样肽-1受体激动剂在2型糖尿病患者中的应用

Clinical pharmacology and therapy Pub Date : 2022-06-04 DOI: 10.32756/0869-5490-2022-2-63-68

O. Suprun, A. Bagriy, E. Mykhailichenko, M. Krivushcheva

引用次数: 0

Potential clinically significant drug interactions of drugs with fruit and berry juices 药物与水果和浆果汁的潜在临床显著药物相互作用

Clinical pharmacology and therapy Pub Date : 2021-11-13 DOI: 10.32756/0869-5490-2021-4-44-51

A. Pereverzev, O. Ostroumova

{"title":"Potential clinically significant drug interactions of drugs with fruit and berry juices","authors":"A. Pereverzev, O. Ostroumova","doi":"10.32756/0869-5490-2021-4-44-51","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-4-44-51","url":null,"abstract":"Any drug can potentially cause adverse drug reactions (ADRs), including serious and fatal. Some of them are caused by interactions with food, in particular, fruit and berry juices. Juices have a complex chemical composition and each of the chemicals can interact with drugs. Grapefruit juice is one of the most popular and well-studed in terms of potential drug interactions juices. Grapefruit juice is an inhibitor of CYP3A enzymes in the intestine involved in the presystemic metabolism of drug substrates. Therefore, it can increase their absorption. Apple juice at a concentration of 5% significantly reduces the activity of OATP, but not the activity of P-glycoprotein, which, for example, leads to a decrease in AUC and Cmax of fexofenadine to 30- 40% relative to the concentration of fexofenadine in patients drinking only water. Taking 200 ml of grape juice can reduce the concentration of phenacetin in blood plasma and increase the ratio of AUC of paracetamol to phenacetin due to the induction of CYP1A2 activity by grape juice flavonoids or by reducing the rate of absorption of phenacetin. To prevent ADRs, it is recommended to take drugs with water and and not consume simultaneously juices that are known to interact with drugs.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73664238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ankylosing spondylitis: diagnostic challenges and efficacy of upadacitinib 强直性脊柱炎:upadacitinib的诊断挑战和疗效

Clinical pharmacology and therapy Pub Date : 2021-11-13 DOI: 10.32756/0869-5490-2021-4-62-70

S. Moiseev, P. Novikov, S. Gulyaev, E. Kuznetsova, T. Shevtsova, I. Shafieva, O. Bugrova

{"title":"Ankylosing spondylitis: diagnostic challenges and efficacy of upadacitinib","authors":"S. Moiseev, P. Novikov, S. Gulyaev, E. Kuznetsova, T. Shevtsova, I. Shafieva, O. Bugrova","doi":"10.32756/0869-5490-2021-4-62-70","DOIUrl":"https://doi.org/10.32756/0869-5490-2021-4-62-70","url":null,"abstract":"Ankylosing spondilitis (AS) is a relatively common disease mainly affecting young males and presenting with chronic inflammation of the spine and the sacroiliac joints. AS is one of the forms of axial spondyloarthritis (SpA). Diagnosis of AS is usually delayed on average by 8-10 years from the first symptoms. SpA should be considered both in males and females who present with chronic low back pain starting before the age of 45 years and at least one additional factor (inflammatory back pain, HLA-B27, sacroileitis, peripheral arthritis, enthesitis, dactylitis, psoriasis, uveitis, inflammatory bowel disease, family history for SpA, elevated ESR and/or C-reactive protein, and good response to NSAIDs). Such patients should be referred to rheumatologist. MRI improves early diagnosis of AS since it detects inflammatory changes, which precede structural damage of the sacroiliac joints (nonradiographic SpA). Physical exercises and NSAIDs are the first-line treatment for AS, whereas TNF and interleukin-17 inhibitors are widely used as a second-line therapy. Upadacitinib is the first JAK-inhibitor that was approved for the treatment of active AS in adult patients who have responded inadequately to conventional therapy. The authors discuss clinical cases demonstrating efficacy of upadacinitib in patients with AS.","PeriodicalId":10353,"journal":{"name":"Clinical pharmacology and therapy","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89699400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0